First, studies have shown that approximately 70% of patients with breast cancer are hormone receptor positive (HR+), and most of them are of the HER2−/HR + subtype.43,44 Second, patients with triple-negative breast cancer (TNBC) with pathogenic BRCA1/2 mutations had higher PCR rates with or without carboplatin in the GeparSixto study (66.7% vs 36.4%, OR 3.50; 95% CI: 1.39-8.84; P = .008).19 Our results appear to complement the study, where HR+/HRD-high predicted a worse prognostic outcome. The gene discussed is ERBB2; the disease is breast cancer.